[Changes in C100-3, and N14 antibodies in patients with chronic hepatitis C treated with interferon].
In interferon therapy for chronic hepatitis type C, we assayed C100-3 and N14 antibodies, and also determined IgM-C100-3 and IgM-N14 antibodies as well as HCV-RNA. N14 antibody was assayed by an end point titer method. In patients responding to interferon therapy, C100-3 and N14 antibody titers were decreased and became negative. In patients irresponsive to interferon therapy, C100-3 antibody titers were hardly changed, while N14 antibody titers were markedly increased. IgM-C100-3 and IgM-N14 antibody levels were significantly higher in the patients non-responding to interferon therapy than in those responding to interferon therapy. The daily assays of C100-3 and N14 antibody titers are considered useful in judging the effectiveness of interferon against chronic hepatitis type C.
Sakurai
K
K
Department of Clinical Laboratory, Kitasato University East Hospital, Sagamihara.
Yagi
K
K
Hanawa
Y
Y
Shibuya
A
A
Shibata
H
H
Uchiyama
Y
Y
Ohtani
H
H
D000956:Antigens, Viral; D002908:Chronic Disease; D006508:Hepatitis Antibodies / Q000378:metabolism*; D006526:Hepatitis C / Q000276:immunology / Q000628:therapy*; D018937:Hepatitis C Antibodies; D006801:Humans; D007075:Immunoglobulin M / Q000378:metabolism*; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage*; D008297:Male; D008875:Middle Aged; D011994:Recombinant Proteins; D017361:Viral Nonstructural Proteins / Q000276:immunology*
D000956:Antigens, Viral; C064544:C100 protein, hepatitis C virus; D006508:Hepatitis Antibodies; D018937:Hepatitis C Antibodies; D007075:Immunoglobulin M; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D017361:Viral Nonstructural Proteins